Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Essler

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
EULAR Rheumatology Open|June 29, 2026
Molecular imaging and immune cell adhesion via vascular adhesion protein-1 in idiopathic inflammatory myopathy: a case reportSimon M Petzinna, Jim Küppers, Maike S Adamson, et al.
Molecular Imaging and Biology|October 12, 2010
Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRIKen Herrmann, Ralph A Bundschuh, Robert Rosenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 9, 2012
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrestMario Vallon, Christof Seidl, Birgit Blechert, et al.
International Journal of Endocrinology|February 25, 2020
Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive CasesKarin Mayer, Selina Kiry, Anna Yordanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
Impact of Initial Prostate-Specific Membrane Antigen PET/CT Staging and Prostate-Specific Membrane Antigen-Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase 2 DEPROMP TrialPhilipp Krausewitz, Markus Essler, Florian C Gaertner, et al.
Scientific Reports|June 24, 2024
Clinical experience with shear wave elastography (SWE) for assessing healthy uterus in a transabdominal approachJudith M Stader, Florian Recker, Tolga Tonguc, et al.
European Radiology|November 29, 2024
Ultrasound-guided high-intensity focused ultrasound for symptomatic uterine fibroids: clinical outcome of two European centersSara Dohmen, Florian Recker, Yoana Ivanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Markus Essler, Kim M Pabst, et al.
Oncotarget|January 11, 2015
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myelomaKatharina Teiluf, Christof Seidl, Birgit Blechert, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
EULAR Rheumatology Open|June 29, 2026
Molecular imaging and immune cell adhesion via vascular adhesion protein-1 in idiopathic inflammatory myopathy: a case reportSimon M Petzinna, Jim Küppers, Maike S Adamson, et al.
Molecular Imaging and Biology|October 12, 2010
Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRIKen Herrmann, Ralph A Bundschuh, Robert Rosenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 9, 2012
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrestMario Vallon, Christof Seidl, Birgit Blechert, et al.
International Journal of Endocrinology|February 25, 2020
Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive CasesKarin Mayer, Selina Kiry, Anna Yordanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
Impact of Initial Prostate-Specific Membrane Antigen PET/CT Staging and Prostate-Specific Membrane Antigen-Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase 2 DEPROMP TrialPhilipp Krausewitz, Markus Essler, Florian C Gaertner, et al.
Scientific Reports|June 24, 2024
Clinical experience with shear wave elastography (SWE) for assessing healthy uterus in a transabdominal approachJudith M Stader, Florian Recker, Tolga Tonguc, et al.
European Radiology|November 29, 2024
Ultrasound-guided high-intensity focused ultrasound for symptomatic uterine fibroids: clinical outcome of two European centersSara Dohmen, Florian Recker, Yoana Ivanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Markus Essler, Kim M Pabst, et al.
Oncotarget|January 11, 2015
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myelomaKatharina Teiluf, Christof Seidl, Birgit Blechert, et al.
Pageof 21